Biomedical subjects

M Rosenblat

Publications and source records attributed to M Rosenblat.

30 records · Page 2Linked to original sources

PubMed1996

Activation of NADPH oxidase required for macrophage-mediated oxidation of low-density lipoprotein.

Low-density lipoprotein (LDL) oxidation by arterial wall cells, a key event during early atherogenesis, was suggested to involve the activation of 15-lipoxygenase and/or nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. We sought to analyze the role of these oxygenases in macrophage-mediated oxidation of LDL under oxidative stress. Upon incubation of LDL with the J-774 A.1 macrophage-like cell line or with human monocyte-derived macrophages (HMDM) in the presence of 1 micromol/L CuSO4, the release of superoxide anions to the medium was demonstrated. Under these conditions, the cytosolic protein components of the NADPH oxidase complex, P-47 and P-67, translocated to the plasma membrane, indicating LDL-mediated activation of the NADPH oxidase complex. Under the above-mentioned experimental conditions, the macrophage 15-lipoxygenase was also activated, as determined by the release of 15-hydroxy-5,8,11,13-eicosatetraenoic acid (15-HETE) and 13-hydroxyoctadecadienoic acid (13-HODE) to the medium. Inhibition of the macrophage NADPH oxidase with apocynin or dismutation of superoxide anions, the product of NADPH oxidase activation, with superoxide dismutase (SOD) significantly inhibited macrophage-mediated oxidation of LDL (by 61% to 89%) under these conditions. Phorbol myristate acetate (PMA), which causes NADPH oxidase activation in J-774 A.1 macrophages, had no significant effect on 15-lipoxygenase activity, but still resulted in cell-mediated oxidation of LDL. Finally, HMDM from two patients with chronic granulomatous disease (CGD) that were shown to lack active NADPH oxidase, but to possess almost normal 15-lipoxygenase activity failed to oxidize LDL. We thus conclude that LDL-induced NADPH oxidase activation (under oxidative stress) is required for macrophage-mediated oxidation of LDL, whereas activation of 15-lipoxygenase may not be sufficient for LDL oxidation under these conditions.

Adolescent↗

PubMed1996

Phospholipase A2 and phospholipase D are involved in macrophage NADPH oxidase-mediated oxidation of low density lipoprotein.

Macrophage-mediated oxidation of low density lipoprotein (LDL) under oxidative stress induces activation of reduced nicotinamide adenine dinuleotide phosphate (NADPH) oxidase. Using J-774 A.1 macrophages, the present study demonstrates that phospholipase A2 (PLase A2) as well as phospholipase D (PLase D) are involved in macrophage NADPH oxidase-mediated oxidation of LDL. Furthermore, the products of these phospholipases, arachidonic acid and phosphatidic acid, can induce NADPH oxidase activation, followed by cell-mediated oxidation of LDL. This LDL oxidation was shown to be dependent on extracellular calcium ions. We conclude that PLase A2 and PLase D can induce macrophage NADPH oxidase-dependent oxidation of LDL and thus can contribute to the formation of atherogenic oxidized lipoprotein.

Arachidonic Acid↗

PubMed1995

Reduced cellular cholesterol content in peroxisome-deficient fibroblasts is associated with impaired uptake of the patient's low density lipoprotein and with reduced cholesterol synthesis.

Mammalian cells acquire cellular cholesterol by de novo synthesis as well as by uptake of low density lipoprotein (LDL). Peroxisomes contain enzymes involved in the synthesis of cholesterol, and peroxisome-deficient (PD) patients have been shown to have hypocholesterolemia and abnormal LDL. We therefore decided to study whether cholesterol synthesis and cellular uptake of LDL are impaired in cultured PD fibroblasts. The present study demonstrates a significantly lower cellular cholesterol mass in fibroblasts from three PD patients, as compared to control cells (41-59% of controls). The rate of cholesterol synthesis was also reduced in all three PD cell lines, being 16-20% of the control values. LDL binding and degradation by fibroblasts were 3- to 5-fold higher in the PD cells as compared to control cells. Similarly, enrichment of normal fibroblasts with tetracosanoic acid (C-24:0), a situation that could mimic the in vivo accumulation of very long chain fatty acid (VLCFA) in PD cells, caused LDL binding and degradation to be 4-fold higher than in non-treated cells. On the other hand, the uptake of LDL derived from PD patients by normal fibroblasts was markedly reduced (by up to 67%) in comparison to the cellular uptake of normal LDL. Similar results were obtained in PD cells. This study demonstrates a lower cellular cholesterol content and reduced cholesterol synthesis rate in PD cell lines. In addition, we demonstrate that regulation of the uptake of normal LDL by cellular LDL receptors is operative in PD cells, whereas LDL derived from PD patients is not recognized normally by the LDL receptor.(ABSTRACT TRUNCATED AT 250 WORDS)

Cholesterol↗

PubMed1994

Macrophage-mediated oxidation of extracellular low density lipoprotein requires an initial binding of the lipoprotein to its receptor.

Cells of the arterial wall including macrophages were shown to oxidize low density lipoprotein (LDL) in vitro. Upon incubation of LDL with J-774.A1 macrophage-like cell line for 18 h in the presence of 1 microM CuSO4, extensive macrophage-mediated oxidation of the LDL fatty acids and cholesterol moieties was demonstrated. Similar results were found with mouse peritoneal macrophages or human monocyte-derived macrophages. Several lines of evidence suggest that LDL binding to the LDL receptor on macrophages is required for the cell-mediated oxidation of LDL. 1) Incubation of the cells in the presence of monoclonal antibody to the LDL receptor (IgG-C7), substantially inhibited lipoprotein oxidation. 2) Pretreatment of LDL with monoclonal antibodies to the LDL receptor binding domains on the LDL apoB-100 (mAbs B1B6 and B1B3) inhibited cell-mediated oxidation of LDL by 52-95%. 3) Down-regulation of the macrophage LDL receptors (by preloading the cells with cholesterol) reduced LDL oxidation by 42%. 4) Up-regulation of the LDL receptor (by macrophage incubation in serum-free medium) was associated with 80% elevation in LDL oxidation. 5) Macrophage activation with lipopolysaccharide up-regulated the LDL receptors and was associated with up twofold increase LDL oxidation. 6) Human monocyte-derived macrophages from a patient with homozygous familial hypercholesterolemia, which lack the LDL receptor, failed to oxidize the LDL. 7) On using acetylated LDL or methylated LDL, which do not bind to the LDL receptor, macrophage-mediated oxidation of the lipoprotein did not occur. The binding of LDL to the macrophage LDL receptor under oxidative stress induced the oxidation of extracellular unbound LDL as demonstrated by cell-mediated lipid peroxidation of mAb B1B6-treated LDL by cells that were preincubated with native LDL. Furthermore, macrophage conditioned medium (MCM) that was obtained after 5 h of cells preincubation with native LDL under oxidative stress (1 microM CuSO4), followed by lipoprotein removal and a further 18 h of cell incubation (but not MCM that was similarly obtained without cell preincubation with LDL), was found to contain oxidized linoleic and arachidonic acids and was able to induce LDL lipids peroxidation. In conclusion, macrophage-mediated oxidation of LDL requires an initial binding of the lipoprotein to the LDL receptor on the cell surface under oxidative stress. This interaction leads to the formation and release of cellular oxidized polyunsaturated fatty acids that can oxidize the LDL molecule extracellularly.

Acetylation↗

PubMed1992

Apolipoprotein E and lipoprotein lipase reduce macrophage degradation of oxidized very-low-density lipoprotein (VLDL), but increase cellular degradation of native VLDL.

Oxidized low-density lipoprotein (Ox-LDL) has been shown to be taken up by the macrophage-scavenger receptor at an enhanced rate in comparison to native LDL, with consequent cellular cholesterol accumulation. In the present study, we analyzed macrophage interaction with very-low-density lipoprotein (VLDL) from normolipidemic subjects (N-VLDL) that was oxidized in the presence of 10 mumol/L copper ions. Oxidized VLDL (Ox-VLDL) contained increased conjugated dienes and malondialdehyde (MDA) equivalents and showed increased electrophoretic mobility. Gradual fragmentation of VLDL apolipoproteins (apo) was noted, with apo B-100 being the first to be fragmented, followed by apo E and apo C. Degradation of Ox-VLDL by mouse peritoneal macrophages (MPM) was increased almost twofold in comparison to N-VLDL. Upon incubation of VLDL with lipoprotein lipase (LPL), the LPL-treated lipoprotein demonstrated up to 50% increased degradation by macrophages in comparison to control N-VLDL. However, the degradation of LPL-treated Ox-VLDL was decreased by up to 20% in comparison to control Ox-VLDL. Similarly, the addition of apo E to VLDL enhanced its cellular degradation by 56%, whereas a 20% reduction in the degradation of apo E-treated Ox-VLDL was demonstrated in comparison to nontreated Ox-VLDL. These results showed that LPL and apo E, two important regulatory substances in cellular metabolism of plasma lipoproteins, increased macrophage degradation of native VLDL, but reduced the degradation of Ox-VLDL. These inhibitory effects on macrophage uptake of Ox-VLDL suggest that apo E and LPL may possess antiatherogenic potential.

Animals↗

PubMed1992

Involvement of the macrophage low density lipoprotein receptor-binding domains in the uptake of oxidized low density lipoprotein.

Macrophages, unlike most other cells, possess both low density lipoprotein (LDL) and scavenger receptors. The scavenger receptor has been shown to mediate the uptake of oxidized LDL (ox-LDL), which ultimately leads to cholesterol loading of the macrophages. The present study was undertaken to define epitopes on ox-LDL that are important for lipoprotein binding to macrophages and to ascertain whether ox-LDL can bind to the LDL receptor. Monoclonal antibodies (Mabs) directed against several epitopes along the apolipoprotein B-100 (apo B-100) molecule were used. LDL (300 micrograms/ml) was oxidized by incubation with 10 microM CuSO4 for 24 hours. Ox-LDL, as opposed to acetylated LDL (ac-LDL), reacted with Mabs directed against the LDL receptor-binding domains (Mabs B1B6 and B1B3). Similarly, uptake of ox-LDL but not ac-LDL by a murine J774 macrophage-like cell line was inhibited by as much as 40% after using Mab B1B6. The anti-LDL receptor antibody IgG-C7 also inhibited 125I-ox-LDL uptake by macrophages by 60%. Chromatography on heparin-Sepharose columns of LDL that was partially oxidized for only 3 hours resulted in two fractions: an unbound fraction with characteristics similar to those of ox-LDL and a bound fraction similar to native LDL. Macrophage degradation of the unbound fraction was inhibited by Mab IgG-C7 and Mab B1B6, which are directed toward the LDL receptor and the LDL receptor-binding domains on apo B-100, respectively. When incubated with three types of macrophages, J774 macrophage cells, mouse peritoneal macrophages, and human monocyte-derived macrophages, excess amounts of unlabeled ox-LDL, like native LDL but unlike ac-LDL, substantially suppressed the uptake and degradation of 125I-labeled LDL. Similar studies with fibroblasts, however, revealed that unlabeled LDL but not unlabeled ox-LDL or ac-LDL competed with 125I-LDL for cellular uptake and degradation. Mab directed against epitopes on the amino terminus domain of apo B-100 (C14) demonstrates a similar immunoreactivity with ox-LDL and native LDL but a much lower reactivity with ac-LDL. Mab C14 inhibited macrophage degradation of ox-LDL by 34% but had no inhibitory effect on the uptake of native LDL or ac-LDL. Thus, the ac-LDL and LDL receptor-binding domains as well as a unique epitope on the amino terminus of apo B-100 may be involved in macrophage binding of ox-LDL.(ABSTRACT TRUNCATED AT 400 WORDS)

Animals↗

PubMed1991

Reduced uptake of cholesterol esterase-modified low density lipoprotein by macrophages.

Changes in low density lipoprotein (LDL) lipid composition were shown to alter its interaction with the LDL receptor, thus affecting its cellular uptake. Upon incubation of LDL with 5 units/ml cholesterol esterase (CEase) for 1 h at 37 degrees C, there was a 33% reduction in lipoprotein cholesteryl ester content, paralleled by an increment in its unesterified cholesterol. CEase-LDL, in comparison to native LDL, was smaller in size, possessed fewer free lysine amino groups (by 14%), and demonstrated reduced binding to heparin (by 83%) and reduced immunoreactivity against monoclonal antibodies directed toward epitopes along the LDL apoB-100. Incubation of CEase-LDL with the J-774 macrophage-like cell line resulted in about a 30% reduction in lipoprotein binding and degradation in comparison to native LDL, and this was associated with a 20% reduction in macrophage cholesterol mass. Similarly, CEase-LDL degradation by mouse peritoneal macrophages, human monocyte-derived macrophages, and human skin fibroblasts was reduced by 20-44% in comparison to native LDL. CEase-LDL uptake by macrophages was mediated via the LDL receptor and not the scavenger receptor. CEase activity toward LDL was demonstrated in plasma and in cells of the arterial wall such as macrophages and endothelial cells. Thus, CEase modification of LDL may take place in vivo, and this phenomenon may have a role in atherosclerosis.

Animals↗

PubMed1991

Secretory products from human monocyte-derived macrophages enhance platelet aggregation.

Both macrophages and platelets play an important role in atherogenesis. We studied the effect of conditioned medium obtained from human monocyte-derived macrophages on in vitro platelet aggregation. Incubation of macrophage-conditioned medium (MCM) with platelets resulted in enhanced platelet aggregation (up to 35% difference between basal and MCM-stimulated activity), which was time dependent. This MCM effect on platelet function was increased both with time of mononuclear cell culturing (up to 10 days) and with the time of macrophage incubation in serum-free medium (up to 24 hours) prior to MCM collection. MCM from either cholesterol-loaded macrophages or from macrophages obtained from patients with familial hypercholesterolemia demonstrated a 37% and 20% increased effect, respectively, in comparison to MCM derived from normal subjects. Macrophage activation with lipopolysaccharide resulted in the harvesting of a MCM that enhanced platelet activity 60% more than MCM obtained from nonactivated cells. The active component of MCM was inhibited fivefold following heating at 100 degrees C for 10 minutes or after treatment with trypsin or protease, but was not affected by antioxidants. MCM activation of blood platelets may be of importance in atherogenesis. Understanding the mechanisms involved may contribute to an improved appreciation of the role of both platelets and macrophages in atherosclerosis.

Animals↗

PubMed1989

Modification of LDL by platelet secretory products induces enhanced uptake and cholesterol accumulation in macrophages.

LDL modified by incubation with platelet secretory products caused cholesterol accumulation and stimulation of cholesterol esterification in mouse peritoneal macrophages. Its uptake by the macrophages was a receptor-mediated process, not susceptible to competition by acetyl-LDL or polyanions suggesting independence of the scavenger receptor. Stimulation of the esterification process in macrophages by this modified LDL was inhibited by the lysosomal inhibitor chloroquine, indicating requirement for cellular uptake and lysosomal hydrolysis of the lipoprotein. Within the cell, the modified LDL inhibited cellular biosynthesis of triglycerides in a manner similar to the action of acetyl-LDL but different to the effect of native LDL. In the presence of HDL, acting in the medium as an acceptor for cholesterol, a low rate of cholesterol efflux from cells incubated with this modified LDL as well as with acetyl-LDL was demonstrated. A small reduction in cholesteryl ester synthesis was found in these cells, compared to a 60% reduction in cells incubated with native LDL. Thus it was demonstrated that LDL modified by platelet secretory products could induce macrophage cholesterol accumulation even though it was recognized and taken up via the regulatory LDL receptor.

Adult↗

PubMed1989

Platelet-modified low density lipoprotein induces macrophage cholesterol accumulation and platelet activation.

Low density lipoprotein (LDL), modified by chemical or biological means, was shown to induce macrophage cholesterol accumulation. The cholesterol and protein contents of LDL were decreased (by 10 and 15%, respectively) by incubation of the LDL for 2 h at 37 degrees C with normal washed platelet suspension or with platelet-conditioned medium; these decreases were not affected by platelet activation. The platelet-modified LDL caused a greater increase (by up to 15%) in collagen-induced, in vitro platelet aggregation than control LDL. Incubation of mouse peritoneal macrophages with platelet-modified LDL for 18 h at 37 degrees C resulted in an elevation of the macrophage cholesterol ester content (by 35-50%) as well as an increase in the cholesterol esterification rate (by 40-70%), compared with the effect of control LDL. Macrophage cholesterol synthesis, however, was significantly decreased (by 40-50%), compared with the effect of control LDL. The effect of LDL treated by platelet-conditioned medium was similar to that of platelet-modified LDL. The effect of platelet-modified LDL on macrophage cholesterol esterification was maximal within 24 h of incubation, and it was not significantly affected by inhibition of cholesterol synthesis. The platelet-modified LDL was taken up by the macrophages in a saturable fashion and its uptake was competitively inhibited by LDL, but not by acetylated LDL. We conclude that platelet-modified LDL interacts with the LDL receptor and induces macrophage cholesterol accumulation. Since the modified lipoprotein induces in vitro foam cell formation and platelet activation, platelet-modified LDL could be considered to be pro-atherogenic.

Animals↗

PubMed1986

Plasma lipoprotein and platelet function after heparin injection: studies in normal fasted and postprandial and in type V hyperlipoproteinemic subjects.

The effect of heparin injection (50 IU/kg body weight) on plasma lipoprotein concentration and composition as well as on platelet aggregation and 14C-serotonin release was studied in normal fasted subjects, normal subjects 4 hr after a fatty meal (postprandial state), and in primary type V hyperlipoproteinemic patients. Heparin injection resulted in a reduction in plasma triglyceride, cholesterol, and phospholipids as well as in the inhibition of platelet function in either the presence or the absence of the plasma environment. Heparin injection resulted in catabolism of triglyceride-rich lipoproteins and increment of cholesterol and protein in the high-density lipoprotein (HDL) density range. In fasted normal subjects, very-low-density lipoprotein (VLDL) was reduced by 50%; in the postprandial state, both VLDL and chylomicrons decreased similarly; but in phenotype V hyperlipoproteinemia, only chylomicrons (but not VLDL) degraded. Heparin injection also caused increased electrophoretic mobility of plasma lipoprotein. Upon incubation of similar lipoprotein concentration, derived before and after heparin injection, with normal washed platelets, we found that in all the groups all the lipoproteins (except HDL) derived after heparin injection caused reduction in platelet activity. High-density lipoproteins derived after heparin injection, especially from type V hyperlipoproteinemic subjects, increased normal platelet activity, and this probably represents an effect of chylomicron remnant particles in the HDL density range. Our study thus demonstrates altered composition and concentration of plasma lipoprotein after heparin injection and may suggest the appearance of remnant particles with atherogenic properties.

Adult↗

PubMedDate not supplied

Platelet-modified lipoprotein induced by thrombin: effect of whole blood and plasma.

The effect of thrombin, the platelet-activating agent, on lipids and lipoprotein patterns in humans was studied in whole blood, in platelet-rich plasma (PRP) and in washed platelet/lipoprotein systems. Upon incubation of whole blood at 37 C for 24 h and then centrifugation of the cells, the content of plasma cholesterol and triglyceride decreased. In the presence of thrombin (10 u/ml), plasma high-density lipoprotein (HDL) levels also markedly decreased. In PRP, plasma lipids and lipoproteins were reduced to a lesser extent than in platelet-poor plasma (PPP). In the presence of thrombin, plasma HDL was decreased in PRP, but not in PPP. The electrophoretic mobility of low-density lipoprotein (LDL) was increased following incubation of whole blood, PRP or PPP, but decreased in the presence of thrombin. When washed platelets were incubated with LDL or HDL for 24 h at 37 C, there was a significant increment in the lipid and protein content of the lipoprotein medium, resulting from platelet-released particles; this phenomenon was increased in the presence of thrombin and more so with LDL. LDL--but not HDL--electrophoretic mobility was increased following incubation with washed platelets, but thrombin caused a reduction in lipoprotein electrophoretic mobility. This study demonstrates that platelets affect lipid and lipoprotein patterns and this is influenced by thrombin treatment. Platelets release lipid-protein particles, which then interact with and modify the lipoprotein.

Adult↗